Key points from article :
MUVON Therapeutics, a pioneering biotech company, has been accepted into the prestigious Wyss Zurich accelerator program as of April 2021. Wyss Zurich, a collaborative initiative of the University of Zurich and ETH Zurich, is dedicated to advancing regenerative medicine, robotics, and hybrid technologies. Made possible by Swiss philanthropist Dr. Hansjörg Wyss, the program brings together multidisciplinary teams of leading experts to transform cutting-edge research into real-world clinical applications.
With Wyss Zurich's support, MUVON will focus on advancing its Mesenchymal Progenitor Cell (MPC) therapy for stress urinary incontinence. This includes conducting a phase II clinical trial to evaluate the treatment’s efficacy. The collaboration also grants MUVON access to state-of-the-art GMP (Good Manufacturing Practice) facilities and specialized platform teams, accelerating its path toward commercialization.
This partnership builds on a successful earlier collaboration under the MUS.I.C. project, which laid the groundwork for producing clinical-grade therapies. Together, MUVON and Wyss Zurich aim to bring innovative solutions to patients, transforming the future of healthcare.
